Guilherme Nader Marta/X
Feb 2, 2025, 01:46
Guilherme Nader Marta: Phase 3 ALEXANDRA/IMpassion030 trial found no benefit of adjuvant atezolizumab and chemo for TNBC
Guilherme Nader Marta, Advanced Clinical Fellow at Dana-Farber Cancer Institute, shared a post on X about a recent paper by Michail Ignatiadis et al. published in JAMA:
“Phase 3 ALEXANDRA/IMpassion030 trial (n=2199) published in JAMA found no benefit of adjuvant atezolizumab and chemo vs chemo alone for high-risk early-stage TNBC (IDFS HR 1.11, 95% CI 0.87-1.42).
Higher grade 3-4 toxicity (54% vs 44%).”
Authors: Michail Ignatiadis et al.
More posts featuring Guilherme Nader Marta.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 2, 2025, 05:53
Feb 2, 2025, 05:26
Feb 2, 2025, 05:24
Feb 2, 2025, 04:46
Feb 2, 2025, 04:22
Feb 2, 2025, 04:00
Feb 2, 2025, 03:22
Feb 2, 2025, 03:20